Clinical Trials
11 trialsNCT05431270 2026-05-19
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT04165070 2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT02382406 2023-05-23
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03361319 2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2 Withdrawn
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT00073723 2016-12-15
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Celgene Corporation
Phase 1/2 Completed
NCT00544648 2014-06-09
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated